Chris J Watson1,2,3, Joe Gallagher4,5, Mark Wilkinson5, Adam Russell-Hallinan6, Isaac Tea7, Stephanie James5, James O'Reilly4, Eoin O'Connell5, Shuaiwei Zhou5, Mark Ledwidge4,5, Ken McDonald4,5. 1. Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, Belfast, BT9 7BL, Northern Ireland. chris.watson@qub.ac.uk. 2. Conway Institute, University College Dublin, Dublin 4, Ireland. chris.watson@qub.ac.uk. 3. St. Vincent's University Hospital Healthcare Group, Dublin 4, Ireland. chris.watson@qub.ac.uk. 4. Conway Institute, University College Dublin, Dublin 4, Ireland. 5. St. Vincent's University Hospital Healthcare Group, Dublin 4, Ireland. 6. Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, Belfast, BT9 7BL, Northern Ireland. 7. Internal Medicine, Lankenau Medical Center, Wynnewood, PA, 19096, USA.
Abstract
BACKGROUND: The purpose of this study was to investigate the utility of BNP, hsTroponin-I, interleukin-6, sST2, and galectin-3 in predicting the future development of new onset heart failure with preserved ejection fraction (HFpEF) in asymptomatic patients at-risk for HF. METHODS: This is a retrospective analysis of the longitudinal STOP-HF study of thirty patients who developed HFpEF matched to a cohort that did not develop HFpEF (n = 60) over a similar time period. Biomarker candidates were quantified at two time points prior to initial HFpEF diagnosis. RESULTS: HsTroponin-I and BNP at baseline and follow-up were statistically significant predictors of future new onset HFpEF, as was galectin-3 at follow-up and concentration change over time. Interleukin-6 and sST2 were not predictive of future development of new onset HFpEF in this study. Unadjusted biomarker combinations of hsTroponin-I, BNP, and galectin-3 could significantly predict future HFpEF using both baseline (AUC 0.82 [0.73,0.92]) and follow-up data (AUC 0.86 [0.79,0.94]). A relative-risk matrix was developed to categorize the relative-risk of new onset of HFpEF based on biomarker threshold levels. CONCLUSION: We provided evidence for the utility of BNP, hsTroponin-I, and Galectin-3 in the prediction of future HFpEF in asymptomatic event-free populations with cardiovascular disease risk factors.
BACKGROUND: The purpose of this study was to investigate the utility of BNP, hsTroponin-I, interleukin-6, sST2, and galectin-3 in predicting the future development of new onset heart failure with preserved ejection fraction (HFpEF) in asymptomatic patients at-risk for HF. METHODS: This is a retrospective analysis of the longitudinal STOP-HF study of thirty patients who developed HFpEF matched to a cohort that did not develop HFpEF (n = 60) over a similar time period. Biomarker candidates were quantified at two time points prior to initial HFpEF diagnosis. RESULTS:HsTroponin-I and BNP at baseline and follow-up were statistically significant predictors of future new onset HFpEF, as was galectin-3 at follow-up and concentration change over time. Interleukin-6 and sST2 were not predictive of future development of new onset HFpEF in this study. Unadjusted biomarker combinations of hsTroponin-I, BNP, and galectin-3 could significantly predict future HFpEF using both baseline (AUC 0.82 [0.73,0.92]) and follow-up data (AUC 0.86 [0.79,0.94]). A relative-risk matrix was developed to categorize the relative-risk of new onset of HFpEF based on biomarker threshold levels. CONCLUSION: We provided evidence for the utility of BNP, hsTroponin-I, and Galectin-3 in the prediction of future HFpEF in asymptomatic event-free populations with cardiovascular disease risk factors.
Authors: Robb D Kociol; Peter S Pang; Mihai Gheorghiade; Gregg C Fonarow; Christopher M O'Connor; G Michael Felker Journal: J Am Coll Cardiol Date: 2010-09-28 Impact factor: 24.094
Authors: T Tsutamoto; T Hisanaga; A Wada; K Maeda; M Ohnishi; D Fukai; N Mabuchi; M Sawaki; M Kinoshita Journal: J Am Coll Cardiol Date: 1998-02 Impact factor: 24.094
Authors: Alan S Maisel; Kevin S Shah; Denise Barnard; Brian Jaski; Geir Frivold; John Marais; Maged Azer; Michael I Miyamoto; Dawn Lombardo; Damon Kelsay; Navaid Iqbal; Pam R Taub; Ken Kupfer; Elizabeth Lee; Paul Clopton; Michael Zile; Barry Greenberg Journal: J Card Fail Date: 2015-10-31 Impact factor: 5.712
Authors: Ross T Campbell; Pardeep S Jhund; Davide Castagno; Nathaniel M Hawkins; Mark C Petrie; John J V McMurray Journal: J Am Coll Cardiol Date: 2012-11-07 Impact factor: 24.094
Authors: Umesh C Sharma; Saraswati Pokharel; Thomas J van Brakel; Jop H van Berlo; Jack P M Cleutjens; Blanche Schroen; Sabine André; Harry J G M Crijns; Hans-J Gabius; Jos Maessen; Yigal M Pinto Journal: Circulation Date: 2004-11-01 Impact factor: 29.690
Authors: Rudolf Berger; Martin Huelsman; Karin Strecker; Anja Bojic; Petra Moser; Brigitte Stanek; Richard Pacher Journal: Circulation Date: 2002-05-21 Impact factor: 29.690
Authors: Aftab Jan; Ian Dawkins; Niamh Murphy; Patrick Collier; John Baugh; Mark Ledwidge; Kenneth McDonald; Chris J Watson Journal: ScientificWorldJournal Date: 2013-12-25
Authors: Paolo Morfino; Alberto Aimo; Vincenzo Castiglione; Giuseppe Vergaro; Michele Emdin; Aldo Clerico Journal: J Cardiovasc Dev Dis Date: 2022-08-10